Blocking immunoglobulin G (IgG) inhibits complement-mediated killing of serum-resistant Neisseria gonorrhoeae (GC) in immune human serum. We examined the mechanism of action of blocking IgG. Presensitization of GC with increasing concentrations of blocking IgG or F(ab')2 before incubation with bactericidal antibody and absorbed pooled normal human serum increased consumption and deposition of the third component of human complement (C3) and the ninth component of human complement (C9) but inhibited killing in dose-related fashion. We next showed that blocking IgG or F(ab')2 partially inhibited binding of bactericidal IgG to GC. Also, binding of a monoclonal antibody recognizing GC outer membrane protein PIl was almost completely inhibited by blocking F(ab')2, confirming other work (Rice, P. A., M. R. Tam, and M. S. Blake, manuscript submitted for publication) showing that PIl is a target for blocking antibody. Studies of the C3 deposition site showed that one quarter of the C3 deposited on GC in the presence of blocking IgG bound covalently to the antibody molecule. Finally, 125I-GC constituents with covalently bound C3 were affinity purified on Sepharose bearing antibodies to C3 and identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis. C3 deposition on a 40,000-mol wt surface protein was enhanced six-to ninefold by blocking IgG, which indicates that the site of complement deposition was altered by blocking antibody. These studies show that blocking IgG competes with bactericidal antibody for binding to GC, but enhances rather than blocks complement activation, and leads to complement deposition at new sites that do not result in serum killing.
Introduction
Direct complement-mediated killing of gram-negative bacteria may both require and be blocked by antibody within human serum. This enigma is perhaps most clearly apparent for serum killing of Neisseria gonorrhoeae (GC).' Clinical isolates of GC require antibody for killing. Natural bactericidal antibody for serum-sensitive isolates ofGC is present in normal human serum (1, 2) , and bactericidal antibody for serum-resistant isolates is often present in convalescent human disseminated gonococcal infection (DGI) serum (3) (4) (5) . However, the presence of IgGclass blocking antibodies, which are often found in normal human serum, may preclude killing of serum-resistant strains of GC (6, 7) .
The mechanism of action of the blocking antibody for GC is not known. Unlike blocking antibody for Neisseria meningitidis (8) , which is of the IgA isotype and therefore is unable to activate complement efficiently, the capacity of blocking IgG to interfere with complement activation by GC has not been tested. It has been speculated that the blocking IgG for GC and for other gram-negative organisms (9-11) may be predominantly those isotypes of IgG that activate complement poorly. Implicit within this assumption is the idea that blocking antibody competes with or displaces complement-activating bactericidal antibody from the bacterial surface. Neither the capacity ofblocking antibody to activate complement nor its capacity to displace or compete for binding with bactericidal antibody have been tested.
We report here studies of these issues. Our results indicate that blocking IgG enhances rather than inhibits complement consumption and deposition on GC, leading to complement deposition at new sites on the outer membrane. Furthermore, blocking IgG and blocking F(ab')2 inhibit binding ofbactericidal antibody to GC.
Methods
Strains. A single serum-resistant strain (WG) of GC was used for all experiments. This strain was isolated from the joint of a patient with DGI, and has been used previously (7) . The strain has a protein I (PI) molecular weight of 36, 200 and is in the IB3-serovar group (kindly serotyped by Dr. Joan Knapp, University of Washington, Seattle, WA) (12) . The organism was grown for 20 h in candle extinction jars at 370C on a solid GC agar-base medium (Difco Laboratories, Inc., Detroit, MI) containing 1% Isovitalex. Transparent, nonpiliated colonies were selected as described by Swanson (13) . Bacteria were scraped from plates with a sterile inoculating loop and suspended to the desired optical density at room temperature (RT) in Hanks' balanced salt solution containing I mg/ml human serum albumin (HSA), 0.15 mM CaCI2, and 1.0 mM MgCI2 (HBSS++A). Serum. Convalescent serum from the DGI patient, obtained 22 d after infection with the WG strain, was used as the source ofbactericidal antibody. Bactericidal antibody in this serum is of the IgG isotype and is directed against lipopolysaccharide. Serum obtained from DGI patients in convalescence may express bactericidal activity against strains resistant MgCI2; HSA, human serum albumin; Mab, monoclonal antibodies; Mab 1D3 and Mab 2E6, Mab directed against gonococcal protein I and protein III, respectively; NPGB, nitrophenyl guanidino benzoate; PAGE, polyacrylamide gel electrophoresis; PI, P11, and PIl, proteins I, II, and III, respectively; RT, room temperature; WG, a single serum-resistant strain of GC.
to killing by normal human serum (5, 14) . With the use of a previously reported assay (7), blocking antibody was identified in serum from a normal volunteer. Both convalescent serum and blocking serum were incubated at 560C for 30 min before being used to inactivate complement.
A pool of normal human serum was used as a source ofcomplement activity. Before use, the serum was absorbed at 00C with glutaraldehydefixed strain WG to remove specific antibody, as previously described (15); aliquots ofthe serum were then frozen at -700C (absorbed, pooled normal human serum [Abs PNHS]). Serum absorbed in this way lost <15% of starting hemolytic third component of human complement (C3) activity, as assessed in a standard functional C3 titration (16) . Serum from a patient with acquired hypogammaglobulinemia was used for some experiments (IgG < 20 mg/dl; IgM < 5 mg/dl; and IgA < 4 mg/dl).
Antibody preparation. As previously described (15), IgG was purified from convalescent serum and from blocking serum by both octanoic acid precipitation and batch absorption on Whatman DE52 in 0.05 M acetate buffer, pH 5.2. The resulting IgG was >95% pure, as assessed by densitometric scans ofsamples analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). IgG gave a single precipitin line when tested by double diffusion analysis with antiserum to whole human serum (Miles Laboratories, Elkhart, IN). Bactericidal IgG was iodinated with Iodobeads (Pierce Chemical Co., Rockford, IL) and 1251I Na (New England Nuclear, Boston, MA) to a specific activity of 1.12 X 106 cpm/Mg for use in some experiments. To remove aggregates, we centrifuged aliquots of labeled and unlabeled IgG in an air-driven ultracentrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) for 15 min at 178,000 g before use. F(ab')2 fragments of blocking IgG were prepared exactly as described (17) , except that the F(ab')2 preparation was also absorbed with protein A-Sepharose by incubation of F(ab')2 at 2.0 mg/ml in phosphate-buffered saline (PBS) with 0.2 ml of packed protein A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) per milliliter for 60 min at RT. F(ab')2 fiagments showed no residual IgG when analyzed by SDS-PAGE and did not produce a precipitin line when tested in a double diffusion assay with antiserum to the Fc portion of IgG (Cappel Laboratories, Cochranville, PA).
Monoclonal antibodies (Mab) directed against gonococcal PI (Mab I D3) and protein III (PIII) (Mab 2E6) were prepared and characterized as described previously by Tam et al. (18) and Swanson et al. (19) . Mab 1D3 recognizes PI molecules in the lA-serovar group but not the IBserovar group and therefore does not bind to PI on strain WG; this assessment was made through a negative coagglutination assay (16) Determination of C3 binding to biotinylated blocking IgG during serum incubation. The binding of C3 to biotinylated blocking IgG on GC during serum incubation was measured using minor modifications of recently reported methods (22, 23) . Briefly, purified blocking IgG was biotinylated with n-hydroxysuccinimide biotin (Calbiochem-Behring Corp., La Jolla, CA), then used at a final concentration of 800 Ag/ml to presensitize GC in HBSS++A. Presensitized organisms were then incubated for 45 min at 370C in 20% Abs PNHS containing 125I-C3, with or without added bactericidal antibody, or in 20% A56 Abs PNHS containing '25I-C3. Additionally, GC not presensitized with biotinyl blocking IgG were incubated concomitantly in 20% Abs PNHS that contained '25I-C3. After incubation, bacterial pellets were washed twice in HBSS++ that contained 1 mg/ml of HSA and 25 MM nitrophenyl guanidino benzoate (NPGB); then the pellets were solubilized in 100 Ml of 1% SDS at 1000C for 5 min. Insoluble material was removed by centrifugation for 2 min at 12,500 g. The supernatants were diluted with 2 vol of 0.1 M Tris buffer (pH 8.5) containing 0.25 M NaCl, 0.3% SDS, 1% Triton X-100, and 25 MM NPGB (buffer A) and applied to 100 Ml of packed avidin agarose (Sigma Chemical Co.). The mixtures were rotated overnight at RT and washed five times in buffer A, and 12sI-C3 bound to the resin was determined by counting in a gamma scintillation counter.
Determination of C3 acceptor on GC. The site of C3 deposition on GC was determined in the presence and absence of blocking antibody, with the use of modifications of previously described procedures (24, 25) . The method is based on affinity-purification of surface-iodinated GC constituents that bear covalently attached C3 after being incubated in serum. These constituents are then identified by SDS-PAGE. Bacteria were surface-iodinated with '251I-Na (New England Nuclear) as previously described (15) . '2514(C were suspended in HBSS++A so thata 1:10 dilution gave OD60 = 0.15, then 250-MA aliquots were incubated for 30 min at RT with 50 Ml of either blocking serum or buffer. In one experiment, organisms were presensitized with 10 Ml of bactericidal antibody. The bacteria were pelleted by centrifugation, and the pellets were resuspended in 250 Ml of HBSS++A. These suspensions were mixed with an equal volume of either 20% Abs PNHS or 20% A56 Abs PNHS, and incubation was continued for 40 min at 37°C. The organisms were washed twice, and the washed pellets were solubilized in 100 Ml of 1% SDS for 5 min at lOO°C. The detergent-insoluble residue (containing <10% of'251 cpm) was removed by centrifugation for 2 min at 12,500 g, and the solubilized supernatant was diluted to 2.5 nil (final SDS concentration = 0.04%) with 0.05 M Tris, 100 mM NaCl buffer (pH 8.0) containing 2% Nonidet P-40, 0.5% sodium deoxycholate, 10 mg/ml of HSA, 25 Mm NPGB, and 0.02% NaN3 (buffer B). The mixture was precleared by rotation for 1 h at RT with 250 Ml of Sepharose 4B (5-7% of 125I cpm removed), then the supernatant was applied to 125 Ml of Sepharose 4B to which antibodies to human C3 had been coupled (A:C3 Sepharose). The mixture was rotated for 3 h at RT; the resin was then washed four times with buffer B, and the counts per minute of the 1251 that remained bound to the A:C3 Sepharose were determined. At this point, the A:C3 Sepharose bore C3 with covalently attached '25I-GC constituents. To release bound '25I-GC from A:C3 Sepharose and to cleave ester linkages between C3
and GC acceptor molecules, we incubated the A:C3 Sepharose for 30 min at 37°C in 2 ml of buffer B (without HSA), pH 10.5, containing 1 M NH20H. The A:C3 Sepharose was removed by centrifugation, and the supernatant was dialyzed overnight at 4°C vs. methanol to precipitate released proteins. The flocculent precipitate was collected by centrifugation at 12,500 g, solubilized in SDS sample buffer, and analyzed by 10% SDS-PAGE autoradiography, as previously described (23) .
Results
Consumption of C3 from Abs PNHS by WG. We first wanted to determine whether blocking antibody inhibited complement activation by WG during incubation in serum. WG was presensitized with increasing concentrations of purified blocking IgG, then incubated in 10% Abs PNHS in the presence or absence of convalescent DGI serum that contained bactericidal antibody (Fig. 1) (Fig. 4) (32) that blocking IgG in the same serum source used in these studies is almost exclusively IgG3, an isotype with poor protein A reactivity via the Fc region (28) .
Next, the capacity of blocking serum and other antibody sources to inhibit binding of 1251-bactericidal IgG to WG was we have shown that blocking antibody inhibits binding of IgG within convalescent serum to WG. The capacity of F(ab')2 blocking antibody to inhibit the binding of the PII Mab 2E6 to WG was also tested. As shown in Fig. 4 , nearly 75% inhibition of 2E6 binding occurred at a concentration of F(ab')2 blocking antibody of only 16 Aog/ml. This efficient inhibition suggests that F(ab')2 blocking antibody is directed, at least in part, against PIII. Determination of C3 binding to biotinylated blocking IgG during serum incubation. We have recently shown that immune IgG bearing covalently bound C3b has enhanced bactericidal activity for E. coli 01 1 1 and we have suggested that formation ofC3b-IgG complexes may be critical for effective bacterial killing by complement (23) . We therefore considered the possibility that the blocking IgG for GC did not serve as an acceptor for C3 deposition during complement activation. GC presensitized with biotinylated blocking IgG were incubated in serum that contained '251I-C3, and the percentage of C3 covalently attached to biotinyl lgG was determined by affinity purification of the SDS-solubilized organisms on avidin agarose (Table II) . Between 18.9 and 24.4% of C3 attached to GC was bound to biotinyl blocking IgG, in comparison to -1% binding in controls. C3 binding to blocking IgG was not significantly altered by bactericidal antibody, although we have recently found (not shown) that bactericidal IgG for WG serves as an acceptor for C3 deposition. These results indicate that the blocking IgG on GC serves as an acceptor for C3 deposition and that antibody molecules that bind C3 during complement activation are not necessarily bactericidal.
Determination ofC3 acceptor site on GC. We examined the possibility that the site of C3 deposition (C3 acceptor) on GC was different, depending on whether blocking IgG was present or absent. Surface-iodinated GC were presensitized with blocking IgG or bactericidal antibody, incubated in serum, and the 1251 gonococcal constituents bearing C3 were affinity-purified on A:C3 Sepharose (Table III) . Significantly more 1251I-GC bound to A:C3 Sepharose for samples incubated in 20% Abs PNHS than for the control sample incubated in 20% A56 Abs PNHS. Interestingly, presensitization with blocking antibody did not increase binding of 1251-GC to A:C3 Sepharose in comparison with organisms not incubated with antibody, despite leading to more C3 deposition on the bacterial surface (Fig. 2) .
'251-GC constituents linked to C3 by an ester bond were released with hydroxylamine (>87% release) and analyzed by 10% SDS-PAGE (Fig. 6) . The only major difference between used at a concentration fivefold lower than the concentration of blocking antibody did not change the C3 acceptor site (not shown). Earlier data indicated that this amount of bactericidal antibody rendered the organism susceptible to complement-mediated killing without significantly increasing either C3 consumption or deposition (Figs. 1 and 2 ). These results indicate that blocking antibody changes the C3 acceptor on GC.
Discussion
We have shown in this paper that blocking IgG and F(ab')2 enhance complement consumption and deposition on a serumresistant strain of GC, although they inhibit killing of the organism. Complement deposition is increased through C9, as shown by binding C9 to the bacterial surface. Blocking IgG and F(ab')2 are in part directed against an antigenically conserved gonococcal outer membrane protein, PIII (19) . These blocking antibodies or fragments compete with binding of bactericidal IgG to the strain. These results suggest that the mechanism of action of blocking antibody is to replace binding of bactericidal IgG with an antibody that leads to deposition of nonbactericidal COb-9.
We have demonstrated previously (15, 20, 29) that serumresistant GC activate complement and that complement components are deposited on the outer membrane ofthese organisms without causing killing. Bactericidal rabbit antibody for GC functions by altering the site of deposition or molecular configuration of the COb-9 that attaches to the bacterial surface (15, 29) . Recently, we have also shown that murine Mab directed against identical or closely associated surface-exposed epitopes on gonococcal PI differ markedly in bactericidal activity, despite leading to deposition of nearly equivalent numbers of C9 molecules per organism (20) . The (20) . Thus, it is neither surprising nor unexpected, given the proximity of PI, PIII, and lipopolysaccharide within the gonococcal outer membrane (37) (38) (39) , that blocking F(ab')2 directed against PIII may inhibit binding of bactericidal antibody directed against either lipopolysaccharide or PI.
The capacity of serum-resistant strains of GC to activate the alternative pathway in the absence of serum killing has been shown previously (40) . F(ab')2 fragments of blocking antibody activated and deposited C3 on WG. F(ab')2 fragments cannot activate complement via the classical pathway, but are capable ofinitiating or facilitating alternative pathway activation in many systems (reviewed in reference 41). It is possible, therefore, that blocking antibody mediated alternative pathway activation in the experiments of Densen et al. (40) .
Blocking IgG alters the site of C3 deposition on GC, both by serving as an acceptor for C3 deposition and by redirecting C3 deposition to different bacterial constituents. The percentage of '251I-GC constituents that are affinity-purified on A:C3 Sepharose is lower in the presence than in the absence of blocking IgG (Table III) ; this is due in part to the fact that a substantial fraction ofC3 deposited by blocking IgG is bound to the antibody itself. It is also possible that blocking IgG redirects C3 to nonlabeled constituents, such as lipopolysaccharide, or that multiple C3 molecules are deposited on individual gonococcal constituents. These experiments do not exclude the possibility that the redistribution of C3 initiated by blocking IgG may be a passive phenomenon dictated by a masking of certain C3 acceptor sites by the blocking IgG molecule. This possibility is supported by the observation that C3 deposition is directed to a 40,000-mol wt constituent on GC presensitized with blocking IgG; yet the blocking antibody itself recognizes predominantly PIll (Rice, P. A., M. R. Tam, and M. S. Blake, manuscript submitted for publication) and does not recognize the 40,000-mol wt molecule by immunoprecipitation.
. For the studies reported here, the entire IgG fraction of blocking serum was used rather than affinity-purified antibodies directed against specific gonococcal constituents. Therefore, it cannot be assumed that antibodies with different antigen specificities within the blocking IgG preparation will activate complement equivalently. Nonetheless, we suggest that it is either the nature of the antibody itself or the location of the epitope recognized by the antibody, rather than the antigenic specificity of antibody, that determines bactericidal activity. Such a premise is based on the fact that different Mab, all directed at a single protein PI, can vary in bactericidal activity for GC (20) and that the PIII Mab 2E6 is bactericidal for some strains of GC at high concentrations (Joiner, K. A., and J. Swanson 
